SML2489
Tasquinimod
≥98% (HPLC)
Synonyme(s) :
1,2-Dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide, ABR-215050, ABR-5050, N-Methyl-N-(4-trifluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carboxamide
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C20H17F3N2O4
Numéro CAS:
Poids moléculaire :
406.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderassay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
FC(F)(F)c1ccc(cc1)N(C)C(=O)c2[c]([n](c3c(c2O)c(ccc3)OC)C)=O
InChI
1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
InChI key
ONDYALNGTUAJDX-UHFFFAOYSA-N
Biochem/physiol Actions
Tasquinimod is an antineoplastic agent with immunomodulatory, anti-angiogenic and anti-metastatic activity. It showed good results in overall survival improvement in castrate resistant prostate cancer. Its mechanism of action is not known, but may involve Protein S100-A9 also known as migration inhibitory factor-related protein 14 (MRP-14).
immunomodulator that inhibits tumor angiogenesis; antineoplastic
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Andrew J Armstrong et al.
JAMA oncology, 4(7), 944-951 (2018-05-26)
Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely visualized using the technetium Tc 99m (99mTc) bone scan; however, the standard interpretation of bone scan data relies
K Fizazi et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 28(11), 2741-2746 (2017-10-24)
This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or
Yongquan Wang et al.
Journal of cancer research and clinical oncology, 144(9), 1751-1768 (2018-05-26)
Castration-resistant prostate cancer (CRPC) refers to prostate cancer that has progressed after initial androgen deprivation therapy (ADT). Over the years, treatment strategies for metastatic CRPC (mCRPC) have undergone considerable changes. We performed a network meta-analysis to assess the effectiveness and